Effectiveness of local application of antiseptic with octenidin dihydrochloride molecule in smoking women with ASC-US and LSIL





Pap test, ASC-US, LSIL, smoking, human papillomavirus, microbiota, colposcopy, antiseptic, Prodexin


This article presents the results of our own experience of topical use of the Prodexin antiseptic that is contained an octenidine dihydrochloride molecule as a monotherapy for ASC-US and LSIL cervical pathology (identified with in fluid cytology) associated with human papillomavirus in smoking women.
Study objective: To study the efficacy of topical application of the octenidine dihydrochloride molecule in the Prodexin vaginal suppositories in the treatment of smoking women with ASC-US and LSIL.
Materials and methods. The study involved 45 female smokers with identified ASC-US or LSIL. The complex of examination included: Pap test based on liquid cytology, testing for human papillomavirus 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 types in a quantitative format, screening for the causes of vaginitis, extended colposcopy to exclude cervical intraepithelial neoplasia II+. Prodexin suppositories were used according to a 3-month treatment regimen (20 suppositories daily, and then 10 suppositories in two consecutive cycles).
Results. Clinical and laboratory assessment of the therapy effectiveness has convincingly shown its positive effect on the vagina and cervix. Treatment with the Prodexin antiseptic associated with microbiota normalization, colposcopic picture improvement and changes in the Pap smear to NILM I or II. Regress to NILM was recorded in 20 (86.9%) patients with ASC-US and in 15 (68.8%) women with LSIL.
Conclusions. Prodexin allows to avoid a worsening of the situation and prevent the changes progression in HSIL. Proposed treatment had no side effects, was convenient to use and did not require additional visits to doctor during therapy. The control over the human papillomavirus and study of the viral load has been postponed for 6–12 months from the beginning of the examination, that will be the second stage of work.

Author Biography

O.O. Akulina, Kharkiv Medical Academy of Postgraduate Education

PhD, associate professor, Department of Obstetrics, Gynecology and Oncogynecology


  1. Bagirov, N.S., Petukhov, I.N., Dmitriev, N.V., Grigoryevskaya, Z.V. “The microbiome and cancer: is there a connection? Literature review.” Malignant tumors 8.3 (2018): 56–69.
  2. Breeze, B. “Efficiency and tolerance of antiseptic drugs for the treatment of vaginal dysbiosis during pregnancy.” Journal of obstetrics and gynecology 283 (2011): 585–90.
  3. Vasilchenko, O.N., Baev, O.R. “Efficiency of treatment of bacterial vaginosis in pregnant women with an antiseptic of octenidine dihydrochloride.” Medical advice 12 (2016): 21. DOI: 10.21518/2079-701X-2016-12-21-23
  4. Vovk, І.B., Kaliuta, A.O. “Particularities of clinical interruption of chronic genital inflammation in pathology of uterine cervix associated with HPV infection in women of reproductive age.” Oncology 22 (2020): 3–4.
  5. Vorobiev, S.L., Ivanova, T.M., et al. Cytological screening for cervical cancer. Liquid cytology. Cytological examination of cervical biomaterial (Papanicolaou staining, ThinPrep® technology). Moscow (2018): 25 p.
  6. Diakova, V.M., Potapov, V.O., Akulina, O.O., et al. “HPV-associated pathology of the cervix: the current strategy of diagnostics, treatment and prevention.” Gynecology. Obstetrics. Reproductology 2.34 (2019).
  7. Dikke, G.B. “Pathological vaginal discharge: diagnosis and treatment.” Doctor.Ru 6.150 (2018): 26–9.
  8. Dikke, G.B. «Polymicrobial associations in the etiology of inflammatory diseases of the genitals in women.” Obstetrics and gynecology 6 (2017): 151–8.
  9. Dziublyk, I.V., Kovaliuk, O.V. “Papilomavirus infection: a doctor-virologist look at the problem.” Ukrainian chemotherapy journal 1–2.25 (2012): 98–106.
  10. Brief information about clinical trials of Octenisept®. Available from: [https://orion-med.ru/document/download/1563].
  11. Lakhno, I.V. “Modern possibilities of diagnostics of the vaginal biotope lesions.” “Taking care of the woman” journal 1–2.103–104 (2020).
  12. Meiskens, F., Patel, D. Cervical cancer prevention: tobacco and human papilloma virus. Clinical lecture. Chao family cancer center, University of California, Irvine, USA (2016).
  13. Mitra, A., McIntyre, D.A., Marchezi, J.R., et.al. “Vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what we know and where are we moving on?” Microbiome 4 (2016): 58.
  14. Radzinsky, V.E., Khamoshina, M.B., Shelenina, L.A., et al. “Therapy of vaginal infections: the edge of the problem (international realities and Russian experience.” Doctor.ru 7.85 (2013): 13–7.
  15. Rykova, O.V., Bogomaz, T.P. “Cytological conclusion according to the terminological system The Bethesda 2014: what's new?” Woman's health 3.119 (2017): 82–4.
  16. A modern view on antiseptics. Pharmacological Gerald. [Online]. Available from: [https://pharmvestnik.ru/content/articles/sovremennyj-vzgljad-na-antiseptiku.html].
  17. Tatarchuk, T.F., Kalugina, L.V., Petrova, G.A., et.al. “Vaginal discharge syndrome. Problem with many unknowns.” Reproductive endocrinology 3.53 (2020): 102–8.
  18. Tatarchuk, T.F., Kalugina, L.V., Mamonova, T.O. “Elimination of dysbiosis in women from pathology of the cervix uterus.” Reproductive endocrinology 2 (2011): 30–2.
  19. Tikhomirov, A.L., Kazenashev, V.V., Yudina, T.A. “Effective antiseptic in modern gynecology.” Russian medical journal 24.15 (2016): 993–6.
  20. ML “DILA”. “Traditions and innovations in the diagnosis of cervical pathology. Continuity or contradictions? ML ‘DILA’ – multilevel support of the doctor in diagnostic search of the best decision. Materials of scientific and practical conference with international participation and the plenum of the Association of obstetricians and gynecologists of Ukraine ‘Topical issues of maternity and childhood protection in Ukraine’. Kyiv, 09.24.2015.” Health of Ukraine 3.19 (2015): 36–7.
  21. Brotman, R.M., Shardell, M.D., Gajer, P., et al. “Interaction between temporal dynamics of vaginal microbiota and detection of human papillomavirus.” J Infect Dis 210.11 (2014): 1723–33.
  22. Casper, G.R., Ostor, A.G., Quinn, M.A. “A clinicopathologic study of glandular dysplasia of the cervix.” Gynec Oncol 64.1 (1997): 166–70.
  23. Cirizano, F.D. “Management of pre-invasive diseade of the cervix.” Semin Surg Oncol 16.3 (1999): 222–7.
  24. Ferenczy, A., Coutlee, F., Franco, E., Hankins, C. “Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments.” CMAJ 169.5 (2003): 431–4.
  25. Franco, E.L., Duarte-Franco, E., Ferenczy, A. “Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection.” CMAJ 164.7 (2001): 1017–25.
  26. Fyles, A., Voduc, D., Syed, A., et al. “The effect of smoking on tumour oxygenation and treatment outcome in cervical cancer.” Clin Oncol (R Coll Radiol) 14.6 (2002): 442–6.
  27. Ho, G.Y., Kadish, A.S., Burk, R.D., et al. “HPV 16 and cigarette smoking as risk factors for high-grade cervical intraepithelial neoplasia.” Int J Cancer 78.3 (1998): 281–5.
  28. International Collaboration of Epidemiological Studies of Cervical Cancer. “Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies.” Int J Cancer 118.6 (2006): 1481–95.
  29. Lee, J.E., Lee, S., Lee, H., et al. “Association of vaginal microbiota with human papillomavirus infection in a cohort of Korean twins.” PLoS One 8.5 (2013): e63514.
  30. Long, W., Yang, Z., Li, X., et al. “HPV-16, HPV-58, and HPV-33 are the most carcinogenic HPV genotypes in Southwestern China and their viral loads are associated with severity of premalignant lesions in the cervix.” Virology Journal 15 (2018): 94.
  31. McCann, M.F., Irwin, D.E., Walton, L.A., et al. “Nicotine and cotinine in the cervical mucus of smokers, passive smokers, and nonsmokers.” Cancer Epidemiol Biomarkers Prev 1.2 (1992): 125–9.
  32. Seiser, S., Janker, L., Zila, N., Mildner, M. “Octenidine-based hydrogel shows anti-inflammatory and protease-inhibitory capacities in wounded human skin.” Scientific Reports 11 (2021): 32.
  33. Ostor, A.G. “Natural history of cervical intraepithelial neoplasia: a critical review.” Int J Gynecol Pathol 12.2 (1993): 186–9.
  34. Zhou, Y., Wang, L., Pei, F., et al. “Patients with LR-HPV infection have a distinct vaginal microbiota in comparison with healthy controls.” Front Cell Infect Microbiol 9 (2019): 294. DOI: 10.3389/fcimb.2019.00294
  35. Dopcea, G.N., Dopcea, I., Nanu, A.E., et al. “Resistance and cross-resistance in Staphylococcus spp. strains following prolonged exposure to different antiseptics.” Journal of Global Antimicrobial Resistance 21 (2020): 399–404.
  36. Roteli-Martins, C.M., Panetta, K., Alves Vam Siqueira, S.A., et al. “Cigarette smoking and high-risk ВПЛ DNA as predisposing factors for high-grade cervical intraepithelial neoplasia (CIN) in young Brazilian women.” Acta Obstet Gynecol Scand 77.6 (1998): 678–82.
  37. Segondi, M., Ngou, J., Kelly, H., et al. “Diagnostic value of human papillomavirus (HPV) 16 and HPV 18 viral load in detecting high-grade cervical intraepithelial neoplasia (CIN2+) in a cohort of African women living with HIV.” J Clin Virol 99–100 (2018): 79–83.
  38. Sherman, М., Schiffman, М, Cox, J.T. “Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS).” J Natl Cancer Inst 94.2 (2002): 102–7. DOI: 10.1093/jnci/94.2.102
  39. Shlay, J.C., Dunn, T., Byers, T., et al. “Prediction of cervical intraepithelial Neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on Papanicolaou smears.” Obstet Gynecol 96 (2000): 410–16.
  40. Sivaranjini, R., Jaisankar, T., Thappa, D.M., et al. “Spectrum of vaginal discharge in a tertiary care setting.” Trop Parasitol 3.2 (2013): 135–9. DOI: 10.4103/2229-5070.122140
  41. Schwartz, S.M., Daling, J.R., Shera, K.A., et al. “Human Papillomavirus and prognosis of invasive cervical cancer: a population-based study.” J Clin Oncol 19.7 (2001):1906–15.
  42. Solomon, D., Davey, D., Kurman, R., et al. “The 2001 Bethesda System. Terminaligy for reporting results of cervical cytology.” JAMA 16 (2002): 2114–8.
  43. Szarewski, A., Jarvis, M.J., Sasieni, P., et al. “Effect of smoking cessation on cervical lesion size.” Lancet 348.9028 (1996): 682–3.
  44. Wright, T.C. Jr., Cox, J.T., Massad, L.S., et al. “Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities.” JAMA 287.16 (2002): 2120–9.



How to Cite

Akulina, O. (2021). Effectiveness of local application of antiseptic with octenidin dihydrochloride molecule in smoking women with ASC-US and LSIL. REPRODUCTIVE ENDOCRINOLOGY, (58), 90–96. https://doi.org/10.18370/2309-4117.2021.58.90-96



Tumors and pretumoral pathology